- Home
- ACOG vs VERU Comparison
ACOG vs VERU Comparison
Compare ACOG & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- VERU
- Stock Information
- Founded
- ACOG 2000
- VERU 1971
- Country
- ACOG Canada
- VERU United States
- Employees
- ACOG N/A
- VERU N/A
- Industry
- ACOG
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ACOG
- VERU Health Care
- Exchange
- ACOG Nasdaq
- VERU Nasdaq
- Market Cap
- ACOG 80.3M
- VERU 85.5M
- IPO Year
- ACOG N/A
- VERU 1990
- Fundamental
- Price
- ACOG $9.68
- VERU $3.33
- Analyst Decision
- ACOG Strong Buy
- VERU Strong Buy
- Analyst Count
- ACOG 1
- VERU 3
- Target Price
- ACOG $20.00
- VERU $33.33
- AVG Volume (30 Days)
- ACOG 71.3K
- VERU 184.5K
- Earning Date
- ACOG 08-14-2025
- VERU 08-12-2025
- Dividend Yield
- ACOG N/A
- VERU N/A
- EPS Growth
- ACOG N/A
- VERU N/A
- EPS
- ACOG N/A
- VERU N/A
- Revenue
- ACOG $4,586,341.00
- VERU $16,886,419.00
- Revenue This Year
- ACOG N/A
- VERU N/A
- Revenue Next Year
- ACOG $149.89
- VERU N/A
- P/E Ratio
- ACOG N/A
- VERU N/A
- Revenue Growth
- ACOG N/A
- VERU 337.24
- 52 Week Low
- ACOG $3.75
- VERU $2.64
- 52 Week High
- ACOG $11.54
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- ACOG 61.46
- VERU 36.37
- Support Level
- ACOG $8.01
- VERU $3.24
- Resistance Level
- ACOG $8.34
- VERU $3.53
- Average True Range (ATR)
- ACOG 0.48
- VERU 0.20
- MACD
- ACOG 0.21
- VERU 0.08
- Stochastic Oscillator
- ACOG 92.47
- VERU 30.61
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.